Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
DATA GRAPHICS | Product Development

Daily Chart: comparing timelines of COVID-19 vaccines

May 29, 2020 2:39 AM UTC

Within a few months, preliminary data could be available from as many as eight more COVID-19 vaccines.

Front-runners Moderna Inc. and CanSino Biologics Inc. have already released early results demonstrating their respective vaccines induced virus neutralizing antibodies in healthy volunteers. Whether the effects are sufficient to confer protection, or whether the pre-existing antibodies against CanSino’s viral vector will limit its utility, remain to be seen (see Making Sense of the Deluge of Early COVID-19 Vaccine Data). ...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article